[Therapeutic effect and pharmacokinetics of transdermal phenazepam preparation in patients with different anxiety disorders].
Clinical investigation of a transdermal phenazepam preparation (phenapercuten) in patients diagnosed with different anxiety disorders revealed an original therapeutic action of the new drug, which included both a selective anxiolytic effect and an activating (antiasthenic) component in the absence of undesired sedative and miorelaxant properties. It is shown that the specific action of phenapercuten is related to features of the pharmacokinetic profile of this transdermal drug that is characterized by a low levels of active compound in the blood plasma and by the absence of peak concentrations. TTS Phenapercuten was most effective in patients with anxiety disorders of simple structure.
O A
OA
Dorofeeva
S A
SA
Siuniakov
V P
VP
Zherdev
G B
GB
Kolyvanov
A A
AA
Litvin
G G
GG
Neznamov
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D055815:Young Adult
D014151:Anti-Anxiety Agents; D001569:Benzodiazepines; C017928:phenazepam